Binding properties of sodium glucose co-transporter-2 inhibitor empagliflozin to human serum albumin: spectroscopic methods and computer simulations.

Journal of Biomolecular Structure & Dynamics
Wenjing WangHui Li

Abstract

Empagliflozin is an oral sodium glucose co-transporter-2 inhibitor for type 2 diabetes mellitus. The interaction between empagliflozin and human serum albumin (HSA) was investigated experimentally and theoretically. Fluorescence quenching and time-resolved fluorescence spectroscopy indicated that the quenching mechanism of empagliflozin and HSA was dynamic and that the effective binding constant at body temperature was 3.495 × 103 M-1. Thermodynamic parameters showed that hydrophobic forces were the major binding force in the interaction between empagliflozin and HSA. Circular dichroism, Fourier transform infrared, and 3 D fluorescence spectroscopy revealed that empagliflozin showed a slight change in secondary structure without changing the basic carbon framework of HSA. Site marker displacement experiments revealed that empagliflozin bound to site I of HSA, which was supported by molecular docking. Molecular dynamic simulations indicated that empagliflozin could bind to HSA stably. This study provided insights into the binding mechanism between empagliflozin and HSA.Communicated by Ramaswamy H. Sarma.

References

Mar 11, 2006·The Journal of Physical Chemistry. B·Pearl Pui Hang ChengRoyce W Murray
Aug 19, 2007·Biochimica Et Biophysica Acta·Andreas Barth
Oct 11, 2008·Chemical Biology & Drug Design·Neelam Seedher, Mamta Kanojia
May 9, 2012·Journal of Pharmaceutical and Biomedical Analysis·Bahram HemmateenejadZahra Rezaei
Jul 3, 2013·Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy·Nahid ShahabadiNeda Hossinpour Moghadam
Jul 9, 2013·Luminescence : the Journal of Biological and Chemical Luminescence·Maryam Mahmoodian MoghaddamJamshidkhan Chamani
Jul 31, 2013·Analytical Biochemistry·Ramachandram BaduguJoseph R Lakowicz
Jan 15, 2014·The Journal of Physical Chemistry. C, Nanomaterials and Interfaces·Krishanu Ray, Joseph R Lakowicz
Apr 11, 2014·Expert Review of Clinical Pharmacology·Muralikrishna Gangadharan Komala, Amanda Mather
Apr 12, 2014·Diabetes Care·Hans-Ulrich HäringUNKNOWN EMPA-REG MET Trial Investigators
Jun 10, 2014·Journal of Photochemistry and Photobiology. B, Biology·Meena KumariRajan Patel
Aug 31, 2014·Food Chemistry·Valentina SinisiFederico Berti
Feb 28, 2015·Food Chemistry·Xiangrong LiYan Lu
May 16, 2015·BioMed Research International·Haifeng HouBaofa Jiang
Oct 7, 2015·Journal of Biomolecular Structure & Dynamics·Ali S AbdelhameedRizwan Hasan Khan
Oct 17, 2015·Journal of Biomolecular Structure & Dynamics·Jitendra Kumar MauryaRajan Patel
Jul 30, 2016·Oxford Medical Case Reports·Nellowe Candelario, Jedrzej Wykretowicz
Aug 2, 2016·Advanced Pharmaceutical Bulletin·Arash KhodaeiParvin Zakeri-Milani
Mar 8, 2019·Journal of Biomolecular Structure & Dynamics·Xiaoyue SunZhe Song

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
circular dichroism
fluorescence
fluorescence spectroscopy

Software Mentioned

YASARA

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.